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Abstract 
Background: Loop diuretics are given to the majority of patients with chronic heart failure 
(HF). Whether the different pharmacological properties of the three guideline-recommended 
loop diuretics result in differential effects on survival is unknown. 
Methods: 6,293 patients with chronic HF using either bumetanide, furosemide or torasemide 
were identified in three European HF registries. Patients were individually matched on both the 
respective propensity scores for receipt of either drug and dose-equivalents thereof. 
Results: During a follow-up of 35,038 patient-years, 652 (53.7%), 2,179 (51.9%), and 268 
(30.4%) patients died amongst those prescribed bumetanide, furosemide, and torasemide, 
respectively. In univariable analyses of the general sample, bumetanide and furosemide were 
both associated with higher mortality as compared with torasemide treatment (HR 1.50, 95% 
CI 1.31-1.73, p<0.001, and HR 1.34, CI 1.18-1.52, p<0.001, respectively). Mortality was higher 
in bumetanide users when compared to furosemide users (HR 1.11, 95% CI 1.02-1.20, 
p=0.01). However, there was no significant association between loop diuretic choice and all-
cause mortality in any of the matched samples (bumetanide vs. furosemide, HR 1.03, 95% CI 
0.93-1.14, p=0.53; bumetanide vs. torasemide, HR 0.98, 95% CI 0.78-1.24, p=0.89; 
furosemide vs. torasemide, HR 1.02, 95% CI 0.84-1.24, p=0.82). The results were confirmed 
in subgroup analyses with respect to age, sex, left ventricular ejection fraction, NYHA 
functional class, cause of HF, rhythm, and systolic blood pressure. 
Conclusions: In patients with HF, mortality is not affected by the choice of individual loop 
diuretics. 
Words: 235 
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Introduction 
Guidelines recommend the use of diuretics to reduce the signs and symptoms of congestion 
in patients with heart failure (HF) [1, 2]. In addition, diuretics appear to reduce the risk of death 
and worsening HF compared with placebo [3, 4]. Approximately 60-90% of patients with HF 
receive at least 1 class of diuretics, particularly a loop diuretic, for the management of acute or 
chronic HF [5-8]. Furosemide is more commonly used than other loop diuretics [5]. 
Supplemental table 1 summarizes the pharmacological differences between bumetanide, 
furosemide and torasemide.  
There is some data suggesting potential benefits from longer acting diuretics such as 
torasemide [9-14] or azosemide [15-17] as compared to furosemide. However, the effects of 
the few available retrospective [18, 19] and prospective [20-22] comparisons of loop diuretics 
on mortality are inconsistent. The studies are limited by remarkable heterogeneity, small 
sample size, poor background HF therapy, or short follow-up duration. 
In the present study, we therefore assessed the relative effectiveness in all-cause mortality of 
the three guideline-recommended loop-diuretics in patients with chronic HF using an 
international, multicenter, propensity score matched approach.  
Methods 
Databases 
Data were extracted from three different European HF databases: the Norwegian HF Registry, 
the HF Registry of the Department of Academic Cardiology, University of Hull, UK, and the HF 
Registry of the University of Heidelberg, Germany. Recruitment was prospective and 
continuous for each database and centre. All patients gave their written informed consent for 
data storage and evaluation. The study conformed to the principles outlined in the Declaration 
of Helsinki and was approved by the local ethics committees.  
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The Norwegian HF Registry was initiated in October 2000 and patients were enrolled from the 
outpatient clinics of 27 recruiting hospitals well distributed in all regions of Norway ranging in 
size and scope from small community to large university hospitals. The participating centres 
recorded their data using a web-based database. 
Patients who attended the community HF clinics of the University of Hull, UK, and the 
University of Heidelberg, Germany, for evaluation of HF were offered inclusion into the local 
HF registries. Since both university hospitals are providers of secondary and tertiary care, the 
registries reflect a broad representation of patients of their respective regions. 
Patient selection and follow-up 
All databases reflect all-comer cohorts. Patients were included after stabilization of both clinical 
status and medication. Baseline visits of Norwegian patients were performed between 2000 
and 2012. For patients from Germany and UK, the respective time periods were 1995-2015 
and 2001-2015, respectively. Patients were eligible for the study if they met all of the following 
criteria: a) attendance at the HF outpatient clinic of any of the participating hospitals, b) written 
informed consent for inclusion into the respective HF registry, c) diagnosis of chronic HF, d) 
treatment with a loop diuretic, and e) reported daily dose of diuretic treatment.  
Medication was at the discretion of the referring physician. As only few patients were treated 
with azosemide (n=0) or piretanide (n=40), the present analysis was restricted to users of the 
three guideline-recommended loop diuretics: bumetanide, furosemide, or torasemide (figure 
1). Dose equivalents were derived from ESC guidelines for the diagnosis and treatment of 
acute and chronic HF [1], and expressed in mg furosemide. For example, daily oral doses of 
10 mg torasemide or 1 mg bumetanide were considered to be equivalent to 40 mg furosemide, 
while daily oral doses of 20 mg torasemide or 2 mg bumetanide were considered to be 
equivalent to 80 mg furosemide. Target doses and dose equivalents for angiotensin converting 
enzyme inhibitors, angiotensin receptor blockers and beta-blockers were also derived from 
ESC guidelines [1]. For example, daily doses of 10 mg ramipril or 20 mg enalapril were 
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considered as 100% dose equivalent, while 5 mg ramipril or 10 mg enalapril were defined as 
50% dose equivalent. Similarly, daily doses of 10 mg bisoprolol or 50 mg carvedilol were 
defined as 100% dose equivalent. 
The diagnosis of HF was established on the basis of typical symptoms and signs associated 
with an objective abnormality of cardiac structure or function on echocardiography, cardiac 
magnetic resonance imaging, or left heart catheterisation [1].  
Baseline characteristics included medical history, physical examination, left ventricular ejection 
fraction (LVEF), blood count and chemistry, and medication. Glomerular filtration rate (GFR) 
was estimated using the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-
EPI) [23]. 
Determination of survival status and follow-up were performed by scheduled visits to the 
outpatient clinic, by telephone calls either to the patients’ homes or to their physicians, or by 
electronic hospital records. For the purpose of the present analysis, patients were censored 
as “alive” at the date of this last contact. In addition, for the Norwegian HF Registry, mortality 
data were obtained at regular intervals from the National Statistics Bureau and no patient was 
lost to follow-up. All-cause mortality was the predefined endpoint of the study. All patients were 
followed for at least 1 month. 
Statistical analysis 
All tests are two-tailed and a P-value of less than 5% was regarded as being statistically 
significant. Variables are presented as mean ± standard deviation, median (interquartile 
range), or number (percentages (%)) as appropriate. Chi-squared tests were used to compare 
frequencies. To test for significant differences between groups, the Kruskal-Wallis test and 
analysis of variance (ANOVA) tests were used where appropriate. 
In order to prevent bias in further statistical analyses due to missing baseline values, we 
performed a multiple imputation analysis with n=100 repetitions using the Markov chain Monte 
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Carlo method [24].This procedure replaces each missing value with a set of plausible values 
that represent the uncertainty about the correct value for imputation. 
Differences in event-free survival between patients treated with bumetanide, furosemide, or 
torasemide were analysed using Cox proportional hazard models and displayed using the 
Kaplan-Meier method. To account for possible confounders, patients were matched with 
respect to diuretic treatment using pairwise bi-level propensity score matching as described 
below. Survival analyses were then repeated in matched cohorts.  
Propensity score calculation and matching 
Propensity scores were calculated as the single composite variable from a non-parsimonious 
multivariate logit-linked binary logistic regression of the baseline characteristics. The loop 
diuretic was the dependent variable [25]. In a first step, propensity scores were calculated 
separately for “bumetanide vs. furosemide”, “bumetanide vs. torasemide”, and “furosemide vs. 
torasemide” as dependent variables. Propensity scores were derived from all baseline 
variables except for loop diuretic dose equivalent, estimated GFR (eGFR) and NT-proBNP 
using the multiple imputed baseline data sets. Dose equivalent of the respective loop diuretic 
was not part of the propensity scores as it was used as a separate matching criterion. eGFR 
and NT-proBNP were excluded due to a large number of missing variables. The logits of the 
probability of receiving a certain loop diuretic according to the respective propensity scores 
formed the basis of three separate matching procedures.  
Patients were individually matched for both the propensity for receiving a particular loop 
diuretic and their dose equivalents. Each matching procedure was performed in two steps. 
Firstly, calliper matching of the propensity score was applied with calliper size predefined as 
0.2 of the standard deviation of the total sample. In a one-pass procedure starting with a given 
patient receiving a certain loop diuretic (e.g. bumetanide), the closest match of a patient 
receiving a different loop diuretic (e.g. furosemide) was identified. Secondly, dose equivalents 
for the loop diuretics were compared. If doses varied ≤10 %, the pair of patients was retained 
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for analysis and removed from the total sample to allow for the next matching cycle to take 
place. If doses varied >10% the pair was rejected. Then the first step of the matching process 
was repeated to identify the next closest match to the given bumetanide patient of the failed 
match according to the propensity score. If a further patient on furosemide was thus identified, 
the second step was repeated. If no match according to the propensity score AND dose 
equivalent could be identified, the bumetanide patient was removed from the total sample and 
the matching cycle started with the next bumetanide patient. 
The matching procedures of patients treated with bumetanide vs. torasemide and furosemide 
vs. torasemide were performed analogously. Owing to this statistical design, the matched 
patients included in each drug cohort differed between comparisons.  
Bias reduction, balance and sensitivity analysis 
The balance of baseline covariates before and after matching was assessed using 
standardised differences [26]. In addition, Chi-squared test, Mann-Whitney-U test, and 
student’s t-test were used to test for differences in baseline variables after matching. As a 
sensitivity analysis to univariable survival analyses in the matched samples, we performed 
multivariable Cox regression analyses including significant covariates in the matched samples. 
Finally, we conducted a formal sensitivity analysis to quantify the degree of a hidden bias that 
would need to be present to invalidate our main conclusions following the method suggested 
by Love [27].  
Subgroups 
Analyses were repeated in pre-specified subgroups of the matched samples with respect to 
age (≤mean vs. >mean), sex, LVEF (≤35 % vs. >35 %), NYHA functional class (I/II vs. III/IV), 
cause of HF (ischaemic vs. non-ischaemic), eGFR (≤60 ml/min/1.73m² vs. >60 ml/min/1.73m²), 
serum potassium level (≤mean vs. >mean) and systolic blood pressure (≤120 mmHg vs. >120 
mmHg). Interaction terms were calculated for each of the predefined subgroups in the 
propensity matched sample. 
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Results 
We identified 9,289 HF patients in the three databases. Figure 1 shows the composition and 
selection flow with respect to the different loop diuretics in our study population. Of 6,293 
patients who met the inclusion criteria outlined above, 3,844 patients (61.1%) were from 
Norway, 1,120 patients (17.8%) were from Germany, and 1,329 patients (21.1%) were from 
England.  
Bumetanide was prescribed for 1,215 patients (19.3%) with a median dose of 1 (1-2) mg/d 
(equivalent to 40 (40-80) mg furosemide per day), furosemide for 4,197 patients (66.7%) with 
a median dose of 40 (40-80) mg/d, and torasemide for 881 patients with a median dose of 20 
(10-20) mg/d (equivalent to 80 (40-80) mg furosemide per day). Baseline characteristics of HF 
patients differed with respect to loop diuretic treatment for a number of variables (table 1). 
Overall, patients receiving torasemide were younger and more likely to be in NYHA functional 
class I than those on bumetanide and furosemide. In addition, the majority of patients using 
torasemide suffered from HF of non-ischaemic origin, while ischaemic HF was common in 
bumetanide and furosemide users. NT-proBNP levels were lower in the torasemide group, 
whereas mean LVEF was <35% in all three treatment groups. In patients using torasemide, 
systolic blood pressure was significantly lower as compared to patients on bumetanide or 
furosemide. 
Total follow-up was 420,467 patient-months (35,038 patient-years) with a median follow-up 
duration of 61 (27-99) months. For bumetanide, median follow-up was 59 (26-98) months, 
whereas it was 67 (31-105) months and 36 (18-69) months for furosemide and torasemide, 
respectively. During that time 3,099 (49.2%) patients died: 652 (53.7%) of those on 
bumetanide, 2,179 (51.9%) of those on furosemide, and 268 (30.4%) of those on torasemide.  
In univariable analyses of the overall cohort, patients prescribed bumetanide and furosemide 
both had higher mortality compared with those prescribed torasemide (HR 1.50, 95% CI 1.31-
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1.73, p<0.001, and HR 1.34, CI 1.18-1.52, p<0.001, respectively). Mortality was higher in 
bumetanide users compared to furosemide users (HR 1.11, 95% CI 1.02-1.20, p=0.01). 
Kaplan–Meier curves for 10-year survival with respect to loop diuretic treatment are shown in 
figure 2 a). 
The matching procedures identified 1,175 pairs, 313 pairs, and 522 pairs patients with similar 
dose-equivalents for each of the three comparisons (bumetanide vs. furosemide, bumetanide 
vs. torasemide and furosemide vs. torasemide). Of these, 1,495 (63.6%), 301 (48.1%), and 
443 (42.4%) patients died during follow-up, respectively. Each of the propensity score 
matching procedures significantly reduced standardized differences below 10% in the absolute 
values for most observed covariates, demonstrating a substantial improvement in the covariate 
balance across the treatment groups (supplemental figure 1 a) and b)). However, matched 
patients treated with bumetanide or furosemide differed with respect to beta-blocker dose 
equivalents, while matched patients using bumetanide or torasemide varied with respect to 
heart rhythm, treatment with angiotensin converting enzyme inhibitors/ angiotensin receptor 
blockers, and beta-blocker dose equivalents. Matched patients with furosemide or torasemide 
treatment varied with respect to height, rhythm, and eGFR. The apparent statistical 
significance of the differences in baseline variables in the matched cohorts may result from 
large sample sizes and might thus not be biologically significant. Detailed descriptions of the 
matched samples are available in supplemental tables 2-4.  
Univariable Cox proportional hazard analyses did not find any significant association between 
the particular loop diuretics prescribed and all-cause mortality in any of the matched samples 
(bumetanide vs. furosemide, HR 1.03, 95% CI 0.93-1.14, p=0.53; bumetanide vs. torasemide, 
HR 0.98, 95% CI 0.78-1.24, p=0.89; furosemide vs. torasemide, HR 1.02, 95% CI 0.84-1.24, 
p=0.82). Results were confirmed after adjusting for significant covariates in the matched 
samples (bumetanide vs. furosemide, HR 1.0121, 95% CI 0.91-1.1214, p=0.85; bumetanide 
vs. torasemide, HR 1.02, 95% CI 0.78-1.33, p=0.89; and furosemide vs. torasemide, HR 1.08, 
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95% CI 0.84-1.39, p=0.57). The Kaplan–Meier curves for survival of matched HF patients with 
respect to loop diuretic treatment are presented in figures 2 b)-d).  
Subgroup analyses essentially confirmed that none of the loop diuretics was superior to one 
of the others, with the exception that furosemide was superior to bumetanide in patients with 
NYHA class III/IV HF symptoms, whereas bumetanide was superior to furosemide in NYHA 
class I/II patients. The relevant plot is shown in figure 3.  
The formal sensitivity analyses indicate only a small residual bias. The respective Γ-values 
were 0.76, 0.73, and 0.84 for bumetanide vs. furosemide, bumetanide vs. torasemide, and 
furosemide vs. torasemide (no residual bias at Γ=1.0). This means that in order to attribute a 
possible survival benefit to an unobserved covariate rather than the receipt of e.g. furosemide 
(vs. torasemide), that unobserved covariate would need to produce a 16% increase in the odds 
of receipt of bumetanide while being a weak predictor of all-cause mortality.  
 
Discussion 
In this European multicentre cohort study of outpatients with chronic HF, we analysed the 
association of treatment with any of the three guideline-recommended loop diuretics 
bumetanide, furosemide, or torasemide and long-term survival. Our main findings are that 
• patient characteristics were different between treatment groups and nations. 
Torasemide users were younger, had lower NT-proBNP levels and a higher eGFR than 
bumetanide and furosemide users. In addition, torasemide users more often had non-
ischaemic HF, comorbidities such as hypertension and diabetes and were less often in 
sinus rhythm. 
• treatment with torasemide appeared associated with lower mortality when compared to 
bumetanide and furosemide therapy in univariable analyses of the general sample, 
only. 
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• after controlling for confounders and loop diuretic dose, no difference in survival was 
noted between the three individual loop diuretics. 
• results were consistent through a range of important subgroups. 
Loop diuretics are an integral part of symptom management in patients with chronic HF. There 
is strong evidence that diuretics relieve symptoms, reduce episodes of decompensation and 
increase exercise capacity in patients with chronic HF [3, 4]. In the present analysis, a total of 
73% of patients included in the three HF registries was treated with a loop diuretic. This number 
is lower when compared to data from hospitalized HF patients included in the US American 
Perspective database [5] but rather similar to other samples of patients with chronic HF [6, 7]. 
In line with previous reports [5, 18], the majority of patients was treated with furosemide. 
However, the proportion of patients using bumetanide or torasemide was higher when 
compared to other available registry data [5, 18].  
In the present study, patients on torasemide were significantly younger and predominantly 
suffered from HF of non-ischaemic origin as compared to patients receiving bumetanide or 
furosemide. In addition, torasemide users tended to have features of less severe HF, leading 
to better survival in an unadjusted model as compared to those treated with bumetanide or 
furosemide. This contrasts to data from other retrospective analyses which reported more 
advanced HF in patients treated with torasemide as compared to furosemide users [18, 19, 
28]. Although the majority of torasemide users had concomitant arterial hypertension, systolic 
blood pressure was significantly lower in patients on torasemide. The cause and effect 
relationship between variables associated with torasemide use is uncertain and requires 
further investigation. For example, patients with low blood pressure may lead clinicians to 
prefer torasemide since its longer half-life may increase tolerability of diuretic treatment. 
Alternatively, low blood pressure may result from the use of higher median diuretic doses 
and/or more extensive background HF or antihypertensive therapy in torasemide users. 
Preclinical and clinical data suggest that there may be beneficial pharmacological and disease-
specific effects with long-acting loop diuretics such as torasemide as compared to short-acting 
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furosemide [9-15, 29-36]. In brief, there is evidence that torasemide reduces aldosterone 
production, myocardial fibrosis, sympathetic activation, and ventricular remodelling [10-12, 14, 
15, 31-33, 36]. In the present study, however, these potential benefits did not translate into 
improved survival with long-acting loop diuretics after risk adjustment.  
Our finding in chronic stable patients is supported by two large retrospective analyses 
comparing furosemide and torasemide following acute decompensation HF [18, 19]. To date, 
there are no adequately powered randomized controlled trials comparing the long-term 
prognostic effects of different loop diuretics. Unlike bumetanide for which there is a dearth of 
clinical studies, a few small prospective studies have compared the effects of torasemide 
versus furosemide. Two open-label, randomized studies showed no difference in mortality 
between torasemide and furosemide users [21, 22], whereas the TOrasemide In Congestive 
HF (TORIC) study suggested a survival benefit with torasemide [20, 37]. However, TORIC was 
an open-label, non-randomised, post-marketing surveillance study with a median follow-up 
duration of only 5.9 months and a low use of standard HF therapies. The Japanese Multicenter 
Evaluation of LOng- versus short-acting Diuretics In Congestive heart failure (J-MELODIC) trial 
is a randomized, open, blinded endpoint trial that compared azosemide with furosemide in 320 
patients with chronic HF [17]. Although azosemide significantly reduced the primary composite 
endpoint of cardiovascular death and unplanned admission to hospital for congestive HF after 
two years of follow-up, no statistically significant differences in cardiovascular mortality or all-
cause death were noted. Again, the trial was not adequately powered to provide statistically 
robust results. In contrast, the present study is the largest analysis to date comparing 
torasemide to furosemide use in a population with chronic HF and the only study that provides 
data on bumetanide use.  
In subgroup analyses of matched patients taking bumetanide or furosemide, we found that 
bumetanide was beneficial in patients with NYHA I/II symptoms, while furosemide was superior 
in NYHA class III/IV patients. There are no other studies against which to compare this finding. 
As bumetanide and furosemide share many pharmacological features, the reason for the 
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heterogeneity of the relative effectiveness over NYHA class subgroups remains unclear. Given 
the number of subgroup analyses being made, we cannot exclude a random result. 
Prospective trials are warranted to clarify the relative effectiveness of loop diuretics in patients 
with HF. 
 
Limitations 
As with any non-randomized, observational design, the present study may be subject to 
unmeasured confounders. Sensitivity analyses cannot prove or rule out the presence of such 
an unmeasured confounder. For example, data on the concurrent use of other diuretics such 
as thiazides were lacking and thus may have biased our results. Due to the retrospective 
design of the present analysis, we cannot comment on the specific reasons for selection of a 
particular loop diuretic nor on medication adherence. In this context, it must be noted that 
torasemide was only used in German patients, while bumetanide was only available in Norway 
and the UK. Young torasemide users are underrepresented in the matched samples since 
patients on bumetanide or furosemide were significantly older than torasemide users. 
Therefore, our conclusions may be transferred to younger torasemide users with caution. Our 
data do not allow identification of patients who either switched from one diuretic to another or 
changed diuretic dosing during follow-up. Also, we cannot comment on changes of other 
covariates over time. Follow-up duration in torasemide users was significantly shorter than in 
furosemide or bumetanide users which may bias outcome analyses. However, our data result 
from comprehensive outpatient databases with continuous, prospective inclusion, and close 
surveillance. The detailed characterization of patients allows consideration of various potential 
confounders through the use of comprehensive propensity score and multivariable Cox 
regression models. The large sample size, long-term follow-up and prospective inclusion of 
patients from three European countries are obvious strengths of the present study. The results 
are therefore likely to be generalizable to other chronic HF populations. However, final 
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evidence regarding the comparative effectiveness of loop diuretics is only possible through an 
adequately powered prospective randomised trial. 
While the available evidence on the comparative prognostic effects of loop diuretics in chronic 
HF is scarce, some studies suggest advantages in HF symptoms and quality of life with the 
use of long-acting diuretics [17, 21, 22, 38]. As follow-up data on hospitalisation rates and 
clinical status were not available in the present study, we cannot comment on these endpoints. 
Due to the low number of patients receiving piretanide or azosemide, our study was restricted 
to patients using bumetanide, furosemide or torasemide. Results may not be transferable to 
patients taking other diuretics than those included in the present analysis. 
There is an on-going debate whether treatment with diuretics has an impact on the prognosis 
of HF patients per se. Due to a lack of adequately powered randomised controlled trials, current 
guidelines acknowledge that diuretic effects on morbidity and mortality are unknown, and no 
specific guidance is provided on loop diuretic choice [1, 2]. While a Cochrane meta-analysis 
suggests that conventional diuretics may reduce the risk of death and worsening HF compared 
to placebo [3, 4], post-hoc analyses from large HF trials as well as a number of retrospective 
studies have reported adverse outcomes in HF patients prescribed loop diuretics [39-44]. As 
our study only included patients receiving loop diuretics, we cannot comment on the overall 
prognostic effect of loop diuretic treatment. 
Lastly, it is arguable that the creation of three individually matched comparisons may yield 
slightly different results as no direct triplets (and thus within triplet comparisons) were formed. 
Therefore, hierarchical chains (if A is superior to B and B to C then A must be superior to C) 
as an alternative sensitivity analysis to our results were not feasible. We preferred individual 
pairwise comparison over triplet comparison as it allows for substantially more patients to be 
matched thus increasing statistical power of each group comparison. This argument, however, 
is purely theoretical as all pairwise comparisons found similar prognostic relevance for all loop-
diuretics examined.  
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Conclusion 
In this European multicentre cohort study of patients with HF, we found no difference in all-
cause mortality for patients treated with bumetanide, furosemide, or torasemide after 
adjustment for covariates and loop diuretic dose. This finding was consistent through a number 
of important subgroups.  
17 
 
References 
[1] Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for 
the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and 
treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed 
with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 
2016;37:2129-200. 
[2] Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, et al. 2013 ACCF/AHA 
guideline for the management of heart failure: a report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 
2013;62:e147-239. 
[3] Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the 
role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol. 
2002;82:149-58. 
[4] Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. Cochrane 
Database Syst Rev. 2012:CD003838. 
[5] Bikdeli B, Strait KM, Dharmarajan K, Partovian C, Coca SG, Kim N, et al. Dominance of furosemide 
for loop diuretic therapy in heart failure: time to revisit the alternatives? J Am Coll Cardiol. 
2013;61:1549-50. 
[6] Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in 
patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21. 
[7] Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective 
aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J 
Med. 2003;348:1309-21. 
[8] McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin 
inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. 
[9] Han LN, Guo SL, Lin XM, Shi XM, Zang CB, Yang LM, et al. Torasemide reduces dilated 
cardiomyopathy, complication of arrhythmia, and progression to heart failure. Genet Mol Res. 
2014;13:7262-74. 
[10] Torafic Investigators Group. Effects of prolonged-release torasemide versus furosemide on 
myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end 
point, active-controlled study. Clin Ther. 2011;33:1204-13 e3. 
[11] Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, et al. Effects of torasemide 
on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive 
heart failure. Heart. 2006;92:1434-40. 
[12] Tsutamoto T, Sakai H, Wada A, Ishikawa C, Ohno K, Fujii M, et al. Torasemide inhibits 
transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 
2004;44:2252-3. 
[13] Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on 
myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 
2004;43:2028-35. 
[14] Yamato M, Sasaki T, Honda K, Fukuda M, Akutagawa O, Okamoto M, et al. Effects of torasemide 
on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 
2003;67:384-90. 
[15] Hisatake S, Nanjo S, Fujimoto S, Yamashina S, Yuzawa H, Namiki A, et al. Comparative analysis of 
the therapeutic effects of long-acting and short-acting loop diuretics in the treatment of chronic 
heart failure using (123)I-metaiodobenzylguanidine scintigraphy. Eur J Heart Fail. 2011;13:892-8. 
[16] Miyata M, Sasaki T, Ikeda Y, Shinsato T, Kubozono T, Furusho Y, et al. Comparative study of 
therapeutic effects of short- and long-acting loop diuretics in outpatients with chronic heart failure 
(COLD-CHF). J Cardiol. 2012;59:352-8. 
18 
 
[17] Masuyama T, Tsujino T, Origasa H, Yamamoto K, Akasaka T, Hirano Y, et al. Superiority of long-
acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J. 2012;76:833-
42. 
[18] Mentz RJ, Buggey J, Fiuzat M, Ersboll MK, Schulte PJ, DeVore AD, et al. Torsemide versus 
furosemide in heart failure patients: insights from Duke University Hospital. J Cardiovasc Pharmacol. 
2015;65:438-43. 
[19] Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, et al. Torsemide Versus 
Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). Am J Cardiol. 
2016;117:404-11. 
[20] Cosin J, Diez J, investigators T. Torasemide in chronic heart failure: results of the TORIC study. 
Eur J Heart Fail. 2002;4:507-13. 
[21] Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, et al. Open-label 
randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am 
J Med. 2001;111:513-20. 
[22] Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with 
chronic heart failure NYHA II to IV--efficacy and quality of life. Eur J Heart Fail. 2003;5:793-801. 
[23] Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) 
creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk 
predictions. Am J Kidney Dis. 2010;55:622-7. 
[24] Mulla ZD, Seo B, Kalamegham R, Nuwayhid BS. Multiple imputation for missing laboratory data: 
an example from infectious disease epidemiology. Ann Epidemiol. 2009;19:908-14. 
[25] Austin PC. Some methods of propensity-score matching had superior performance to others: 
results of an empirical investigation and Monte Carlo simulations. Biom J. 2009;51:171-84. 
[26] Rosenbaum PR. Observational studies. 2 ed. Heidelberg, Berlin: Springer; 2002. 
[27] Love TE. Spreadsheet-based sensitivity analysis calculations for matched samples. . Case 
Western Reserve University.: Center for Health Care Research & Policy; 2008. 
[28] Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, et al. Comparative 
effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT 
trial. Future Cardiol. 2015;11:585-95. 
[29] Bleske BE, Welage LS, Kramer WG, Nicklas JM. Pharmacokinetics of torsemide in patients with 
decompensated and compensated congestive heart failure. J Clin Pharmacol. 1998;38:708-14. 
[30] Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, et al. A reappraisal of loop 
diuretic choice in heart failure patients. Am Heart J. 2015;169:323-33. 
[31] Harada K, Izawa H, Nishizawa T, Hirashiki A, Murase Y, Kobayashi M, et al. Beneficial effects of 
torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly 
symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol. 
2009;53:468-73. 
[32] Matsuo Y, Kasama S, Toyama T, Funada R, Takama N, Koitabashi N, et al. Comparative effects of 
long-acting and short-acting loop diuretics on cardiac sympathetic nerve activity in patients with 
chronic heart failure. Open Heart. 2016;3:e000276. 
[33] Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, 
pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive 
heart failure. Clin Pharmacol Ther. 1995;57:601-9. 
[34] Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Suzuki K, et al. Torasemide, a 
long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. Eur J 
Pharmacol. 2008;581:121-31. 
[35] Veeraveedu PT, Watanabe K, Ma M, Thandavarayan RA, Palaniyandi SS, Yamaguchi K, et al. 
Comparative effects of torasemide and furosemide in rats with heart failure. Biochem Pharmacol. 
2008;75:649-59. 
[36] Watanabe K, Sreedhar R, Thandavarayan RA, Karuppagounder V, Giridharan VV, Antony S, et al. 
Comparative effects of torasemide and furosemide on gap junction proteins and cardiac fibrosis in a 
rat model of dilated cardiomyopathy. Biofactors. 2016. 
19 
 
[37] Cosın J DJ. Effects of type of diuretic on mortality in patients with chronic congestive heart 
failure. Eur J Heart Fail. 2000;2:20-1. 
[38] Noe LL, Vreeland MG, Pezzella SM, Trotter JP. A pharmacoeconomic assessment of torsemide 
and furosemide in the treatment of patients with congestive heart failure. Clin Ther. 1999;21:854-66. 
[39] Pellicori P, Cleland JG, Zhang J, Kallvikbacka-Bennett A, Urbinati A, Shah P, et al. Cardiac 
Dysfunction, Congestion and Loop Diuretics: their Relationship to Prognosis in Heart Failure. 
Cardiovasc Drugs Ther. 2016;30:599-609. 
[40] Dini FL, Ghio S, Klersy C, Rossi A, Simioniuc A, Scelsi L, et al. Effects on survival of loop diuretic 
dosing in ambulatory patients with chronic heart failure using a propensity score analysis. Int J Clin 
Pract. 2013;67:656-64. 
[41] Sargento L, Simoes AV, Longo S, Lousada N, Dos Reis RP. Furosemide Prescription During the Dry 
State Is a Predictor of Long-Term Survival of Stable, Optimally Medicated Patients With Systolic Heart 
Failure. J Cardiovasc Pharmacol Ther. 2016. 
[42] Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, Goto D, Yamada S, Yokoshiki H, et al. Loop 
diuretic use at discharge is associated with adverse outcomes in hospitalized patients with heart 
failure: a report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD). Circ J. 
2012;76:1920-7. 
[43] Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E, et al. Diuretic use, progressive 
heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll 
Cardiol. 2003;42:705-8. 
[44] Domanski M, Tian X, Haigney M, Pitt B. Diuretic use, progressive heart failure, and death in 
patients in the DIG study. J Card Fail. 2006;12:327-32. 
 
20 
 
Table 1: Baseline characteristics of patients with HF stratified by use of loop diuretics 
 All patients  
(n = 6,293) 
Bumetanide  
(n = 1,215) 
Furosemide  
(n = 4,197) 
Torasemide 
(n = 881) 
p-
value 
Age, years 
(n=6,293) 
68.9 ± 12.2 70.6 ± 11.3 70.2 ± 11.3 60.2 ± 12.8 <0.001 
Female, n (%) 
(n=6,293) 
1,704 (27.1) 352 (28.9) 1,151 (27.4) 201 (22.8) 0.006 
BMI, kg/m² 
(n=5,823) 
27.4 ± 5.3 27.7 ± 5.3 27.1 ± 5.2 28.6 ± 5.4 <0.001 
SBP, mmHg 
(n=6,200) 
123 ± 22 123 ± 22 125 ± 22 114 ± 19 <0.001 
HR, 1/min 
(n=6,207) 
70 ± 14 70 ± 14 70 ± 14 71 ± 13 0.029 
Sinus rhythm, n (%) 
(n=6,071) 
3,687 (58.6) 716 (58.9) 2,533 (60.4) 438 (49.7) <0.001 
LVEF, % (n=5,848) 32 ± 11 33 ± 11 32 ± 11 31 ± 13 <0.001 
Cause of HF, n (%) 
(n=6,132) 
    <0.001 
ischaemic 3,276 (54.6) 640 (54.7) 2,323 (56.9) 313 (35.6)  
non-ischaemic 2,855 (45.4) 530 (45.3) 1,760 (43.1) 565 (64.4)  
NYHA class, n (%) 
(n=6,212) 
    <0.001 
I 804 (12.9) 113 (9.4) 478 (11.6) 213 (24.2)  
II 3,157 (50.8) 624 (51.9) 2,218 (53.7) 315 (35.8)  
III 2,174 (35.0) 446 (37.1) 1,385 (33.5) 343 (39.0)  
IV 76 (1.2) 18 (1.5) 49 (1.2) 9 (1.0)  
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Comorbidity, n (%) 
(n=6,293) 
     
Diabetes mellitus  1,469 (23.3) 280 (23.0) 882 (21.0) 307 (34.8) <0.001 
Hypertension 2,582 (41.0) 428 (35.2) 1,426 (33.9) 728 (82.7) <0.001 
COPD/ asthma 816 (12.9) 176 (14.5) 554 (13.2) 86 (9.8) 0.006 
Smoker, n (%) 
(n=6,293) 
    <0.001 
ever 2,182 (34.7) 368 (29.5) 1,385 (33.0) 429 (48.8)  
never 4,111 (66.3) 847 (70.5) 2,812 (67.0) 451 (51.2)  
Sodium, mmol/L 
(n=5,936) 
139 ± 3 139 ± 3 140 ± 3 139 ± 3 <0.001 
Potassium, mmol/L 
(n=5,938) 
4.4 ± 0.5 4.4 ± 0.5 4.4 ± 0.5 4.4 ± 0.5 0.002 
NTproBNP, ng/L 
(n=2,761) 
1,387  
(541-3,178) 
1,463 
(634-3,248) 
1,514 
(636-3,248) 
1,146 
(361-2,849) 
<0.001 
eGFR, 
ml/min/1.73m² 
(n=3,630) 
59 (45-78) 57 (44-73) 58 (44-73) 68 (49-89) <0.001 
Treatment      
ACEI, n (%) 
(n=6,293) 
4,574 (72.7) 871 (71.7) 3,068 (73.1) 635 (72.2) 0.635 
ARB, n (%) 
(n=6,292) 
1,294 (20.6) 244 (20.1) 760 (18.1) 290 (32.9) <0.001 
ACEI and/or 
ARB, n (%) 
(n=6,293) 
5,714 (90.8) 1,098 (90.4) 3,777 (90.0) 839 (95.3) <0.001 
22 
 
ACEI/ARB dose 
equivalent, % 
(n=6,278) 
50 (50-100) 50 (50-100) 50 (50-100) 75 (50-100) <0.001 
Beta-blocker, n 
(%) (n=6,293) 
5,330 (84.7) 1,054 (86.7) 3,444 (82.1) 832 (94.5) <0.001 
Beta-blocker 
dose equivalent, 
% (n=6,124) 
50 (25-100) 50 (25-100) 50 (13-79) 75 (50-100) <0.001 
MRA, n (%) 
(n=6,291) 
2,302 (36.6) 515 (42.4) 1,176 (28.0) 611 (69.4) <0.001 
Loop diuretic 
dose, mg 
furosemide 
(n=6,293) 
40 (40-80) 40 (40-80) 40 (40-80) 80 (40-80) <0.001 
Anticoagulants, 
n (%) (n=6,293) 
3,071 (48.8) 586 (48.2) 1,889 (45.0) 596 (67.7) <0.001 
ASA, n (%) 
(n=6,293) 
2,590 (41.2) 503 (41.4) 1,885 (44.9) 202 (22.9) <0.001 
Statin, n (%) 
(n=6,293) 
3,305 (52.5) 628 (51.7) 2,091 (49.8) 586 (66.6) <0.001 
HF, heart failure; BMI, body mass index; SBP, systolic blood pressure; HR, heart rate; LVEF, left ventricular 
ejection fraction; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; NTproBNP, 
N-terminal pro brain natriuretic peptide; eGFR, estimated glomerular filtration rate using the CKD-EPI (Chronic 
Kidney Disease Epidemiology Collaboration) formula; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; ASA, acetylsalicyl acid. Significant p-
values are written in italics. Numbers in italics show the number of patients with available information on the 
respective variable. 
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Figure legends 
Figure 1: Selection of patients for inclusion in the present analyses 
 
Figure 2: Kaplan–Meier curves for 10-year survival for hospital outpatients with chronic heart 
failure receiving bumetanide, furosemide, and torasemide, respectively: a) general sample, b) 
matched patients with bumetanide or furosemide treatment, c) matched patients with 
furosemide or torasemide treatment, d) matched patients with bumetanide or torasemide 
treatment. 
 
Figure 3:  Cox regression analyses for all-cause mortality regarding loop diuretic use in the 
predefined subgroups for the propensity score matched cohorts. 
Legend: SBP, systolic blood pressure; HF, heart failure; eGFR; estimated glomerular filtration 
rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional 
class. *P for interaction refers to subgroups of each propensity matched sample. 
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Supplemental material 
Tables: 
Supplemental table 1: Pharmacological properties of bumetanide, furosemide and 
torasemide. 
 
Supplemental table 2: Baseline characteristics of matched HF patients with bumetanide or 
furosemide treatment 
 
Supplemental table 3: Baseline characteristics of matched HF patients with bumetanide or 
torasemide treatment 
 
Supplemental table 4: Baseline characteristics of matched HF patients with furosemide or 
torasemide treatment 
 
 
 
Graphics: 
Figure 1: Absolute standardized differences before (a) and after (b) propensity score matching 
comparing covariate values for hospital outpatients with chronic HF receiving bumetanide vs. 
furosemide, bumetanide vs. torasemide, and furosemide vs. torasemide, respectively. 
Legend: BMI, body mass index; SBP, systolic blood pressure; HR, heart rate; LVEF, left 
ventricular ejection fraction; NYHA, New York Heart Association functional class; aHT, arterial 
hypertension; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular 
filtration rate; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
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blocker; MRA, mineralocorticoid receptor antagonist. The dotted green line represents an 
absolute standardized difference of 10%. 
 



